Bellicum (BLCM) Appoints Alan K. Smith As Senior Vice President Of Manufacturing

HOUSTON--(BUSINESS WIRE)--Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of Alan K. Smith, Ph.D., as Senior Vice President of Manufacturing.

"We are pleased to welcome an executive with Alan's level of expertise in the cellular immunotherapy field," said Tom Farrell, Bellicum's President and Chief Executive Officer.

Suggested Articles

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.

The €875 million deal gives Sanofi global rights to therapies that could mitigate an efficacy-limiting shortcoming of anti-CD38 antibodies.

Salk scientists identified genes that control the activity of key immune cells, which could inspire ideas for treating cancer and autoimmune diseases.